PubMed Trending Research Digest — July 24, 2026

Automated digest · 96 articles · 15 research areas · July 24, 2026

Overview

Across this week’s set of studies, a dominant theme is precision targeting—at the level of molecular mechanism, biomarkers, and therapy selection. In cancer, multiple papers connect specific vulnerabilities (e.g., metabolic axes such as ADSL–fumarate, mitochondrial/lysosomal quality-control pathways, and UPS/UFMylation remodeling) to therapeutic opportunities, while structural and mechanistic work (e.g., EGFR dimer organization, proteasome redox sensing, and RNA-modification/R-loop control) refines how to intervene. Parallel clinical advances include intensified or novel regimens (eltrombopag for severe aplastic anemia; CAR T-cell and bispecific/ImmTAC strategies in solid tumors; rechallenge approaches after CDK4/6 inhibitors) and improved stratification frameworks using proteomics, blood biomarkers, and response metrics.

A second major thread is immune modulation—both to treat disease and to understand resistance. Several studies emphasize how immune evasion is engineered by tumors or pathogens (exosome-mediated drug resistance, CD47/SIRPα escape, NOD1/2 macrophage-driven adaptive resistance, and viral syncytia-driven interferon resistance). In neurodegeneration and neuroinflammation, work highlights immune pathway involvement (complement activation in early synucleinopathy) and advances blood-based diagnostic tools (plasma phospho-tau panels, proteomic staging, and NfL endpoint standardization). Together, these findings suggest that immune state—whether in tumors, brain microenvironments, or infection—can be measured, modeled, and targeted.

Finally, the digest includes strong translational and preventive signals in non-oncology domains: improved acute outcomes via cell-derived vesicles after TBI, evidence synthesis for critical-care interventions (hemoperfusion and bicarbonate in severe acidemia), and respiratory/upper-airway therapeutics (prone positioning, tezepelumab endotype-informed benefit, and IL-33 blockade programs). Lifestyle and aging studies further reinforce modifiable risk pathways—through sleep/frailty links, ectopic fat reduction, and guideline-level projections—while emphasizing that effects often depend on exposure pattern, baseline risk, and patient subgroup.

---

Cancer Metabolism & Metabolic Vulnerabilities

Mitochondrial-derived vesicles drive budding-type fission of damaged lysosomes.

Researchers studied how mitochondrial-derived vesicles (MDVs) regulate lysosomal renewal by driving budding-type fission (B-fission) of damaged lysosomes during hypoxia-reoxygenation stress. They found that damaged lysosomes form membrane buds that scission into small, functional lysosomes independently of autophagic lysosome reformation, and mechanistically MDVs deliver the fission adaptor MFF to recruit the dynamin-related GTPase DRP1 to lysosomes. This is significant because it reveals a distinct, MDV–MFF–DRP1 pathway for maintaining lysosomal integrity under stress.

Luo Y, Yu J, Li Z et al. · Nature cell biology · (2026) · 1 citations · View on PubMed ↗

Global, regional, and national burden of road injuries 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

This Global Burden of Disease Study 2023 analysis estimated the global, regional, and national incidence, mortality, and morbidity of road injuries for 204 countries and territories from 1990 to 2023. It quantified trends across multiple road injury types and nature-of-injury categories to identify where the burden remains highest and where intervention gaps persist. These surveillance-grade estimates support monitoring of progress toward the UN Decade of Action for Road Safety targets and guide resource allocation for prevention and trauma care.

The Lancet. Public health · (2026) · View on PubMed ↗ · Free PDF ↗

Structures of dynamic interactors at native proteasomes by PhIX-MS and cryo-electron microscopy.

This structural proteomics study introduced PhIX-MS (photo-induced in situ crosslinking-mass spectrometry) combined with cryo-electron microscopy to capture dynamic, transient interactions at native proteasomes. Applying the workflow to proteasome regulatory particles (RPs), it mapped the redox sensor TXNL1 and its dynamic thioredoxin-like domain near RPN2/PSMD1 and RPN13/ADRM1, including structural resolution of RPs without the proteolytic core particle bound to TXNL1. The results clarify how transient redox sensing is physically organized at the proteasome, informing mechanisms of substrate reduction prior to proteolysis.

Lee K, Negi H, Chen X et al. · Molecular cell · (2026) · View on PubMed ↗

α-fluoro-β-alanine functions as a β-arrestin1-biased ligand of S1PR2 to upregulate DPD expression in cancer cells.

Researchers identified α-fluoro-β-alanine (FBAL), a catabolite of the chemotherapeutic 5-fluorouracil (5-FU), as a β-arrestin1-biased ligand of sphingosine-1-phosphate receptor 2 (S1PR2) in colorectal cancer cells. FBAL promoted GRK6-dependent phosphorylation of S1PR2, increased dihydropyrimidine dehydrogenase (DPD) expression, and thereby drove 5-FU resistance. Clinically, this links a 5-FU metabolite to a specific GPCR signaling bias that could be targeted to overcome or prevent resistance.

Tan M, Shao H, Zhang X et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Mitochondrial SLC25A46 Rewires Fatty Acid Oxidation to Promote Cell Proliferation and Ferroptosis Evasion in Ovarian Cancer by Stabilizing CACT.

This study investigated how mitochondrial SLC25A46 promotes ovarian cancer growth and ferroptosis evasion by rewiring fatty acid oxidation, focusing on CACT stabilization and its interaction with MARCHF5. The key finding was that SLC25A46 upregulation enhanced cell proliferation and ferroptosis resistance by increasing fatty acid oxidation–driven ATP and NADPH production through protection of CACT from MARCHF5-mediated effects. This is significant because it identifies a mechanistic metabolic vulnerability—SLC25A46/CACT axis—that could be targeted to improve ovarian cancer therapy.

Gao Y, Hao J, Zhang X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Pan-cancer proteogenomic interrogation of the ubiquitin-proteasome system.

This study used harmonized pan-cancer proteogenomic data from up to 11 CPTAC cohorts to interrogate how somatic cancer-driver alterations remodel the ubiquitin-proteasome system (UPS) at the protein level, focusing on mutation-driven UPS protein quantitative trait locus (pQTL) signatures. It found that mRNA levels poorly predict UPS protein abundance, that a recurrent set of E3 ligases is dysregulated across cancers, and that TP53 loss (among other somatic mutations) produces coherent UPS pQTL signatures. These findings support mutation-informed, proteome-level targeting of UPS components rather than relying on transcriptomics alone for therapeutic biomarker development.

González-Robles TJ, Khan M, Sastourné P et al. · Cell death and differentiation · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression.

This study evaluated two small-molecule UFMylation inhibitors that target the UFMylation E3 ligase complex core protein DDRGK1—osimertinib (via a covalent mechanism) and CP-24 (non-covalent)—in models of glioblastoma to assess effects on tumor and immune microenvironments. It found that both compounds disrupt the DDRGK1–UFL1 interaction, globally suppress UFMylation, inhibit ER-phagy, and induce ER stress, leading to long-term glioblastoma regression. The results suggest DDRGK1/UFMylation as a druggable vulnerability that can reprogram both tumor biology and anti-tumor immunity.

Tan P, Liu Z, Hu X et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

ADSL drives fumarate mediated scrib-rictor complex formation to promote metastasis dissemination in triple-negative breast cancer.

This study examined how the metabolic enzyme ADSL drives fumarate-mediated SLC7A11? (scrib-rictor complex formation) to promote metastasis dissemination in triple-negative breast cancer (TNBC) using untargeted metabolomics, chemoproteomic succination profiling, interaction assays, and in vivo metastasis models. The authors found that ADSL-driven fumarate promotes formation of the SCRIP? (Scrib-Rictor) complex, thereby enhancing metastatic dissemination in TNBC. These findings link a specific metabolic axis (ADSL–fumarate) to a pro-metastatic signaling complex, suggesting a potential metabolic target for limiting TNBC spread.

Fan Y, He X, Deng W et al. · Molecular cancer · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Immunotherapy & Immune Evasion

NOD1/2 signaling in macrophages drives adaptive immune resistance in cancer.

This study evaluated whether NOD1/2 signaling in macrophages drives adaptive immune resistance to cancer therapies, using murine tumor models and genetic or pharmacologic perturbations of NOD1/2 and RIPK2. It found that genetic ablation of NOD1/2 or RIPK2 and pharmacological inhibition of this pathway reduced adaptive resistance across multiple antitumor modalities, including immune checkpoint blockade, adoptive T-cell therapy, and cytotoxic chemotherapy. The results identify NOD1/2–RIPK2 macrophage signaling as a potential therapeutic target to overcome resistance and improve the durability of cancer immunotherapies.

Wei X, Yang L, Wang Y et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

This phase 1/2 clinical study tested IMC-C103C, a T cell receptor bispecific ImmTAC (MAGE-A4×CD3) targeting HLA-A02:01–presented MAGE-A4, in advanced solid tumors. In HLA-A02:01+ patients receiving weekly intravenous infusions with step-up dosing, the trial evaluated safety and preliminary anti-tumor activity alongside pharmacokinetics, pharmacodynamics, and biomarker responses. The study design and early assessments establish the clinical feasibility of MAGE-A4–directed ImmTAC therapy and inform next-step dose selection and biomarker-driven efficacy evaluation.

Sweis RF, Melero I, Davar D et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease.

This review article synthesized preclinical and clinical evidence for next-generation immunotherapies beyond immune checkpoint blockade, focusing on T cell engagers (TCEs) and antibody-drug conjugates (ADCs) in cancer and immune-mediated inflammatory disorders. It found that TCEs can redirect cytotoxic T cells to target cells independently of MHC restriction, while ADCs deliver cytotoxic payloads via receptor-mediated internalization, potentially addressing resistance and limited autoimmune efficacy of checkpoint inhibitors. The mechanistic comparison provides a framework for selecting and developing TCE/ADC strategies—along with brief discussion of the CD47/SIRPα axis—for improved therapeutic specificity and safety.

Abdelaziz AM, Shokr MM · Biochemical pharmacology · (2026) · View on PubMed ↗

Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma.

This preclinical study investigated a tri-specific NK cell engager designed to therapeutically target CD47 to inhibit multiple myeloma (MM). The key finding was that blocking CD47 signaling with the tri-specific engager enhanced anti-myeloma immune activity by countering CD47-mediated immune escape (via SIRPα-dependent inhibition of phagocytosis and NK function). This is significant for immunotherapy development because it supports a multi-target NK engager approach to overcome resistance in MM.

Sumankan R, Sungwan P, Boonsatit N et al. · Cancer immunology, immunotherapy : CII · (2026) · View on PubMed ↗ · Free PDF ↗

Cigarette Smoke-Exposed Alveolar Epithelial Cell-Derived Exosomes Exacerbate Skeletal Muscle Dysfunction Through HDAC2 Signalling.

This mechanistic study investigated whether exosomes derived from cigarette smoke–exposed alveolar epithelial cells drive skeletal muscle dysfunction in the context of COPD, with emphasis on histone deacetylase 2 (HDAC2) signaling. Using the exosome inhibitor GW4869 in a cigarette smoke exposure model, it found that these exosomes exacerbate skeletal muscle dysfunction by regulating HDAC2-dependent inflammatory transcription pathways. The results support a causal exosome–HDAC2 axis linking lung injury to systemic muscle impairment, identifying potential targets to prevent COPD-related sarcopenia.

Li C, Ou M, Jiang G et al. · Journal of cachexia, sarcopenia and muscle · (2026) · View on PubMed ↗ · Free PDF ↗

γδ T cells show distinct responses to CMV after stem cell transplantation.

This study characterized how γδ T cells respond to cytomegalovirus (CMV) after allogeneic hematopoietic stem cell transplantation (aHSCT) by tracking clones over time. Using longitudinal single-cell RNA sequencing combined with paired T cell receptor sequencing across five post-transplant time points, it found patient-specific expansion of non-Vγ9Vδ2 γδ T cell clones, especially within Vδ1+ and Vδ3+ subsets, associated with differences in CMV reactivation status. The work improves mechanistic understanding of immune reconstitution after aHSCT and may inform monitoring or therapeutic strategies targeting γδ T cell subsets during CMV risk.

Sibbertsen F, Song Z, Ly C et al. · Journal of molecular medicine (Berlin, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Exosomes in cancer drug resistance: dual roles in therapy failure and emerging precision therapeutics.

This review discusses how tumor-derived exosomes contribute to cancer drug resistance while also serving as emerging tools for precision therapeutics. The key finding is that exosomal cargo—including proteins such as P-gp and PD-L1, nucleic acids such as miR-21 and lncRNA H19, and pathway activators like PI3K/AKT and MAPK—can promote therapy failure and immune evasion, leading to the proposed “exosome paradox.” Scientifically, it frames exosome targeting and exosome-based delivery as complementary strategies to overcome resistance and enable more tailored treatments.

Tegegne BA, Belew H, Teffera ZH et al. · Cancer cell international · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Genomics, Epigenetics & RNA Regulation

Promoter strength and position govern promoter competition through transcript-dependent insulation.

This study examined how promoter strength and genomic position govern promoter competition within the Sox2 locus by inserting diverse promoters into defined genomic sites and measuring effects on endogenous Sox2 transcription. It found that the reduction in endogenous Sox2 transcription correlates with inserted promoter strength, that competition requires transcription from the inserted promoter, and that longer transcripts produce more competition via transcript-dependent insulation. Scientifically, these results clarify the rules of promoter competition and provide a mechanistic framework for how regulatory elements influence gene expression in development and disease.

Koska M, Nagano M, Swigut T et al. · Nature genetics · (2026) · View on PubMed ↗

RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity.

This study investigated how the RNA exonuclease REXO4 regulates tumor-associated R-loop biology and immune responses in human cells and mouse models. It found that REXO4 resolves m6A-marked R-loops by 3′–5′ exonucleolytic cleavage of the RNA strand within RNA-DNA hybrids, with m6A promoting REXO4 localization, and that REXO4 loss increases DNA damage, triggering interferon signaling and tumor immune infiltration. These findings link m6A-dependent R-loop homeostasis to anti-tumor immunity and position REXO4 as a potential target for immunomodulatory cancer strategies.

Zhang J, Bao K, Hou Y et al. · Molecular cell · (2026) · View on PubMed ↗ · Free PDF ↗

A genome-wide functional analysis of conserved intronic regions reveals essential roles for speckle-associated retained introns.

Using a genome-wide functional screen with dual CRISPR-Cas editing, this study targeted 2,600 conserved human intronic regions to test their roles in cell fitness, focusing on speckle-associated retained introns in human cells. Deletions of a subset of these conserved “fitness” intronic sequences altered intron retention and host gene expression, and specifically deletions in nuclear speckle-associated retained introns in FNBP4 and DDX5 produced downstream effects on gene regulation and cell growth. The work establishes conserved retained introns as functional regulatory elements, advancing understanding of RNA processing and nuclear speckle biology.

Farhangmehr S, Braunschweig U, Wu M et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

RNA modifications in cancer: regulators of tumor evolution and therapeutic response.

This review summarizes how RNA modifications (including m6A, m1A, m5C, m7G, pseudouridine, and A-to-I editing) are regulated by writers/readers/erasers and how they drive tumor evolution and therapeutic response. The key finding is that dysregulated epitranscriptomic networks can control transcript stability, splicing/translation efficiency, and ultimately cancer progression and treatment sensitivity. Scientifically, it positions RNA-modification machinery as a set of potential therapeutic targets and biomarkers for precision oncology.

Gu X, He Y, Xu Z et al. · Molecular cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.

This review explains tumor evolution using evolutionary principles and highlights how modern technologies (high-throughput sequencing, single-cell and spatial omics, lineage tracing, computational modeling, and noninvasive biopsy) enable dynamic tracking of tumor heterogeneity. The key finding is that these approaches collectively address prior limitations in characterizing evolutionary trajectories in advanced cancer. This supports the development of evolution-informed therapeutic targets and adaptive treatment strategies.

Zhang KY, Zhu XZ, Yan YX et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Signaling Pathways & Targeted Therapeutics

Mechanism of actin thin filament pointed-end elongation by leiomodin.

This mechanistic study investigated how leiomodin (Lmod), particularly leiomodin-2 (Lmod2), promotes actin thin filament pointed-end elongation in striated muscle systems where actin exchange is regulated by capping proteins such as tropomodulin (Tmod) and CapZ. The key finding is that Lmod acts as an additional regulator that enables pointed-end elongation to maintain the uniform length of actin thin filaments in sarcomeres. This advances understanding of the molecular control of sarcomere structure and turnover, with implications for muscle function and disease.

Brotzman SB, Palmer NJ, Boczkowska M et al. · Nature communications · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death.

This study created lysine acetyltransferase (KAT)-based chemically induced proximity (CIP) tools, termed KAT-TCIPs, to induce oncogene-induced cell death in diffuse large B cell lymphoma (DLBCL). By redirecting p300/CBP to activate cell-death networks repressed by the oncogenic driver BCL6, the lead KAT-TCIP reprogrammed the epigenome and initiated apoptosis. The approach provides a mechanistic small-molecule strategy to selectively trigger death of malignant B cells by rewiring transcriptional/epigenetic control nodes.

Nix MN, Gourisankar S, Bowman KJ et al. · Cell · (2026) · View on PubMed ↗

The orchestration of ciliary opus: Interplay of signalling molecules, GTPases, and trafficking machinery.

This review article summarized how primary cilia are assembled and maintained through coordinated signaling, small GTPases, and trafficking machinery. It emphasized interplay among intraflagellar transport (IFT) complexes, the BBSome, and ciliary lipid composition, describing how kinesin-2 and dynein-2 motors traffic receptors and signaling components in and out of the cilium while secondary messengers such as cAMP and Ca2+ tune ciliary signaling. The synthesis highlights actionable molecular “control points” for understanding ciliary dysfunction in development and disease.

Piyush R, Giri P, Shinde SR · Current opinion in cell biology · (2026) · View on PubMed ↗

Ligand regulation and function of preformed EGFR dimers.

This study used cryo-electron microscopy (cryo-EM) to determine the structural basis and ligand regulation of preformed epidermal growth factor receptor (EGFR) dimers in the context of receptor tyrosine kinase activation. The authors provided a detailed structural view showing how preformed EGFR dimers are organized and regulated, refining the classic ligand-induced dimerization model. This mechanistic structural insight can inform rational design of EGFR-targeted therapeutics that exploit dimer conformational states.

Zuo Y, Schwartz HT, Walker K et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond.

This review summarized precision medicine strategies in advanced/metastatic pancreatic cancer, focusing on targeting mutant KRAS and related pathways enabled by emerging KRAS inhibitors and trial data such as RASolute 302. The key finding is that RAS inhibition has demonstrated clinically meaningful activity in metastatic pancreatic cancer, expanding the theoretical eligibility for targeted therapeutics beyond small biomarker-defined subgroups. This is scientifically and clinically significant because it reframes KRAS from “undruggable” to actionable and guides future biomarker-driven treatment development.

Schürmann H, Park W, O’Kane GM et al. · Targeted oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancer.

This review article summarized evidence on tailored strategies to overcome third-generation EGFR TKI resistance in EGFR-mutated non-small cell lung cancer (NSCLC). It organizes resistance mechanisms including on-target EGFR alterations (e.g., EGFR C797S and other secondary kinase domain mutations), off-target pathway activation (e.g., MET or HER2 amplification, RAS-MAPK signaling, and oncogenic fusions), and neuroendocrine transformation to small-cell lung cancer, and discusses corresponding clinical evidence for management strategies (truncated). The significance is that it provides a framework for selecting next-line approaches based on tumor molecular profiling to improve outcomes after failure of third-generation EGFR inhibitors.

Saporita I, Farinea G, Lombardi E et al. · Expert opinion on therapeutic targets · (2026) · View on PubMed ↗

Targeted mRNA Delivery Using Bispecific Antibody-Lipid Nanoparticle Complexes.

This study developed and evaluated targeted mRNA delivery using bispecific antibody–lipid nanoparticle (TbsAb-LNP) complexes that bind both the LNP polyethylene glycol (PEG) component and a cell-surface target. The platform was designed to enable targeted uptake beyond liver (extrahepatic delivery), addressing a key limitation of conventional LNPs, and it was used to model targeted delivery in vitro prior to in vivo testing (full experimental results truncated). Scientifically, this bispecific targeting strategy advances the engineering of cell- and tissue-specific RNA therapeutics for more individualized applications.

Hickey JC, Roach T, Cassaidy B et al. · Molecular pharmaceutics · (2026) · View on PubMed ↗

Inhibition of the Metalloproteinase ADAMTS5 Suppresses Colorectal Cancer Metastasis via the PEDF/Wnt/β-Catenin Pathway.

This experimental cancer study investigated the role of the metalloproteinase ADAMTS5 in colorectal cancer (CRC) metastasis and the signaling pathway involved. It reports that ADAMTS5 is upregulated in CRC tissues and that inhibiting ADAMTS5 suppresses metastasis through the PEDF/Wnt/β-catenin pathway. These findings suggest ADAMTS5 as a therapeutic target to block CRC progression by disrupting Wnt/β-catenin–driven metastatic signaling.

Sun X, Zhang H, Hu Y et al. · Cancer medicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Biomarkers & Disease Stratification

Incidence, risk factors and tumor spectrum of second primary cancers after gastric cancer: a multicenter cohort study with long-term follow-up.

This multicenter cohort study evaluated long-term incidence, risk factors, and tumor spectrum of second primary cancers (SPCs) in gastric cancer survivors who underwent curative-intent radical gastrectomy (2007–2021) in the MAGIS cohort. The key findings (not fully shown in the truncated abstract) focus on quantifying SPC risk over time and identifying clinical factors associated with SPC occurrence, along with detection patterns and stage distribution during follow-up. Clinically, the results aim to guide long-term surveillance strategies after gastrectomy to enable earlier detection and better management of SPCs.

Gao X, Han W, Lu L et al. · BMC medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Single-Cell Analysis of Residual Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy Reveals TFAM-Mediated Immunoregulation in Dendritic Cells.

This study performed single-cell analysis of tumor microenvironment (TME) cells in 14 patients with esophageal squamous cell carcinoma (ESCC) who received neoadjuvant immunochemotherapy (nICT) to relate cellular programs to treatment response. Using nonnegative matrix factorization (NMF), the authors identified immunosuppressive cellular programs associated with minimal or no pathological tumor regression and found TFAM-mediated immunoregulation in dendritic cells linked to differential response. These results suggest TFAM-driven dendritic cell immunoregulation as a mechanistic biomarker and potential therapeutic target for improving nICT responsiveness in ESCC.

Chen L, Feng T, Zhou J et al. · Cancer research · (2026) · View on PubMed ↗

Immune checkpoint profiling of B7-H proteins predicts survival and treatment response in metastatic clear cell renal cell carcinoma.

This retrospective cohort study analyzed primary tumor specimens from 145 patients with metastatic clear cell renal cell carcinoma (ccRCC) to determine whether immune checkpoint profiling of B7-H family proteins predicts survival and treatment response. Immunohistochemistry showed compartmentalized intratumoral heterogeneity for B7-H3, B7-H4, B7-H5, and B7-H7, and the resulting B7-H expression patterns were associated with prognosis and treatment response (full statistical associations truncated). These findings suggest that B7-H protein profiling could serve as a predictive biomarker to stratify metastatic ccRCC patients for immunotherapy responsiveness.

Emaldi M, Rey-Iborra E, Mosteiro L et al. · The journal of pathology. Clinical research · (2026) · View on PubMed ↗ · Free PDF ↗

Anatomical and Histologic Response to Neoadjuvant Therapy: Recurrence Patterns Among Poor Responders. A Multi-institutional Observational Cohort Study.

This multi-institutional observational cohort study evaluated how anatomical response to neoadjuvant therapy (NAT), quantified by the Tumor Burden Score ratio (TBSr), and histologic response, assessed by Tumor Regression Grade (TRG), relate to recurrence patterns after hepatectomy for colorectal liver metastases (CRLM). It found that integrating TBSr with TRG improves characterization of recurrence among poor responders following curative-intent surgery. Clinically, this combined macroscopic–histologic response framework could refine post-hepatectomy risk stratification and follow-up strategies for CRLM patients treated with NAT.

Baldo A, Akabane M, Elemosho A et al. · Annals of surgery · (2026) · View on PubMed ↗

---

Cancer Clinical Trials & Treatment Optimization

First CAR T-Cell Therapy Approved for Solid Tumors.

China studied satricabtagene autoleucel (satri-cel), a claudin 18.2-targeting CAR T-cell therapy, in patients with claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer. In a phase II trial, the CAR T cells increased progression-free survival and overall survival. This regulatory approval highlights a clinically significant step toward CAR T-cell strategies for solid tumors, while underscoring the need for further work to improve efficacy and durability.

Cancer discovery · (2026) · View on PubMed ↗

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.

This study reported 5-year patient-reported outcomes from the phase 3 PACE-B trial in men with localized prostate cancer randomized to stereotactic body radiotherapy (SBRT) versus conventionally fractionated radiotherapy (CRT). At 5 years, urinary incontinence outcomes were favourable and comparable between SBRT and CRT, with leak-free rates reported as 64% (164/…). These long-term PROM data support patient-centered decision-making when choosing between SBRT and CRT for localized prostate cancer.

Cooper S, Patel J, Moore C et al. · European urology · (2026) · View on PubMed ↗ · Free PDF ↗

Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).

This phase II again study evaluated abemaciclib rechallenge in hormone receptor-positive, HER2-negative metastatic breast cancer patients who progressed after abemaciclib plus endocrine therapy, using a single-arm design that switched from AI/tamoxifen to fulvestrant (FUL) or from FUL to AI while continuing abemaciclib. The key finding was that continuing abemaciclib with endocrine therapy after progression produced measurable progression-free survival outcomes in this post–CDK4/6 inhibitor setting. The results are clinically significant because they test whether “rechallenge” can overcome resistance patterns and inform sequencing strategies after prior abemaciclib exposure.

Nishimura M, Kogawa T, Sugiyama K et al. · Breast cancer research and treatment · (2026) · View on PubMed ↗ · Free PDF ↗

TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.

The TANGENT phase III randomized study evaluated emactuzumab, a CSF-1R inhibiting monoclonal antibody, in patients with tenosynovial giant cell tumors (TGCT) who were not suitable for surgery or had high risk of postsurgical recurrence. The trial design targets tumor-associated macrophage reduction by blocking CSF-1R dimerization, aiming to improve clinically meaningful outcomes compared with standard approaches. If successful, this would support a shorter, targeted systemic option for TGCT that may reduce the burden of long-term CSF-1R pathway inhibitor therapy and improve disease control in surgically challenging cases.

Gelderblom H, Palmerini E, van de Sande M et al. · Future oncology (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Caffeine and Cardiovascular Disease: A Scientific Statement From the American Heart Association.

This American Heart Association scientific statement reviewed evidence on caffeine intake and its associations with cardiovascular risk factors and cardiovascular diseases in human populations. It concludes that caffeine’s cardiovascular effects are complex and heterogeneous, often differing by acute versus chronic exposure and by the type of caffeinated source, with many studies suggesting an inverse J-shaped relationship for naturally occurring caffeinated beverages. Clinically, the statement emphasizes that risk assessment should consider exposure pattern and individual propensity rather than assuming a uniform cardiovascular effect of caffeine.

Marcus GM, Hu FB, van Dam RM et al. · Circulation · (2026) · View on PubMed ↗

Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review.

This systematic review assessed whether identical myeloma regimens yield different progression-free survival (PFS) outcomes across newly diagnosed myeloma trials, focusing on regimens using bortezomib, lenalidomide, and dexamethasone (VRd) or lenalidomide/dexamethasone (Rd) without transplant. The review aimed to quantify temporal variability in PFS for these same regimens and identify contributors such as informative censoring and diagnostic reclassification of patients previously labeled as smoldering myeloma (full findings truncated). Methodologically, the work highlights how trial-era changes can bias cross-trial comparisons, which is critical for evidence synthesis and clinical decision-making in multiple myeloma.

Mohyuddin GR, Vaquera-Alfaro HA, Godara A et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.

This analysis studied 310 patients with newly diagnosed multiple myeloma treated with upfront quadruplet therapy plus autologous stem cell transplantation (QUAD + ASCT) to redefine functional high-risk (FHR) multiple myeloma in the modern treatment era. Using progression events and subsequent outcomes, the authors evaluated optimal FHR cutoff definitions and associated factors affecting outcomes after progression (specific cutoff results truncated). Clinically, redefining FHR in the QUAD+ASCT era can improve risk stratification and guide post-progression management strategies.

Ravi G, Dhakal B, Callander NS et al. · Cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

This phase 3 randomized superiority trial (EBMT-SAAWP RACE; NCT02009747) evaluated whether adding eltrombopag to front-line immunosuppressive therapy (horse ATG plus cyclosporine A) improves long-term outcomes in treatment-naive severe aplastic anemia patients. The key finding from the final 2-year analysis was that eltrombopag plus standard IST produced a significantly higher 2-year cumulative incidence of complete response than standard IST alone (62.4% vs the control arm, per the truncated abstract). Clinically, it reinforces eltrombopag as an effective intensification strategy for improving durable hematologic response in severe aplastic anemia.

Risitano AM, Iacobelli S, Kulasekararaj A et al. · American journal of hematology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neurodegeneration & Dementia Biomarkers

Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias.

This study used large-scale plasma proteomics to derive blood-based biomarkers for differential diagnosis and molecular staging across neurodegenerative dementias in 1,318 samples from international cohorts. It identified >200 dysregulated proteins, with glial fibrillary acidic protein increasing along the Alzheimer’s disease continuum and integrin alpha-V and integrin alpha-M consistently reduced across disease groups. The results support proteome-based stratification of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia, potentially enabling earlier and more precise clinical staging.

Bellomo G, Vermunt L, In ‘t Veld S et al. · Nature aging · (2026) · View on PubMed ↗ · Free PDF ↗

Use of blood-based neurofilament light chain as an endpoint in clinical trials of neurodegenerative conditions: a scoping review.

This scoping review examined the use of blood-based neurofilament light chain (serum or plasma NfL) as an endpoint in interventional clinical trials and post hoc analyses for neurodegenerative conditions published from 2013–2024. It found that serum/plasma NfL is increasingly used to quantify neuroaxonal injury and can serve as a trial endpoint, with variability in assay platforms, sampling schedules, and analytical approaches. These findings are important for trial design because standardizing how blood NfL is measured and interpreted could improve comparability and regulatory/clinical translation.

Zheng Y, Bhalala OG, Chin KS et al. · Journal of neurology · (2026) · View on PubMed ↗ · Free PDF ↗

Soluble high-molecular-weight amyloid-β species derived from amyloid-β-laden brains induce cerebral β-amyloidosis.

This study investigated whether soluble high-molecular-weight amyloid-β (Aβ) species (>150 kDa) isolated from amyloid-β-laden brains—using size-exclusion chromatography—from both amyloid-β precursor protein transgenic mice and patients with Alzheimer’s disease can seed in vivo cerebral β-amyloidosis. Intrahippocampal injection of these soluble >150 kDa Aβ species dramatically accelerated β-amyloidosis in transgenic mouse brains compared with controls, whereas lower-molecular-weight species did not show the same effect (details truncated). Scientifically, the results identify a specific Aβ “seed” property (high molecular weight) that can drive plaque-like spreading, improving understanding of Alzheimer’s disease propagation mechanisms.

Kashiwagi-Hakozaki M, Uchigami H, Naka Y et al. · Brain communications · (2026) · View on PubMed ↗ · Free PDF ↗

Distribution of Big Tau Isoforms in the Human Central and Peripheral Nervous System.

This study mapped the distribution of “big tau” isoforms (tau containing exon 4a) across the human central and peripheral nervous system using mass spectrometry–based sequencing. It reports that big tau isoforms have distinct anatomic localization compared with canonical “small” tau and assesses their relevance in postmortem tissues from Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and controls. By defining where big tau is expressed and how it may change in neurodegeneration, the work supports isoform-specific biomarkers and mechanisms for tauopathies.

Koppisetti RK, Barthélemy NR, Horie K et al. · Annals of neurology · (2026) · View on PubMed ↗

Blood-based multimodal biomarker models for differentiating early-onset Alzheimer’s disease from frontotemporal dementia: a longitudinal study of early-onset dementia and family members (LEAF) study.

This longitudinal LEAF study assessed blood-based multimodal biomarker models to differentiate early-onset Alzheimer’s disease (EOAD) from early-onset frontotemporal dementia (EOFTD) in patients aged ≤65 years, measuring plasma p-tau217, p-tau181, neurofilament light (NfL), and GFAP by immunoassay. The key finding was that plasma p-tau217 and p-tau181 showed high discriminative performance (AUC 0.831 and 0.862, respectively) for distinguishing EOAD from EOFTD. This is significant because it supports the use of plasma phospho-tau biomarkers—alone and in multimodal panels—for earlier, blood-based differential diagnosis in early-onset dementias.

Kwon HS, Moon SY, Hwang M et al. · Journal of neurology · (2026) · View on PubMed ↗

---

Neuroinflammation, Microglia & Neuroimmune Mechanisms

Microglial states revisited: from homeostasis to disease.

This review article examined how microglial states vary across development, brain region, sex, age, genotype, and environment, focusing on evidence from single-cell/single-nucleus transcriptomics, chromatin accessibility profiling, and spatial multi-omics. It found that microglia occupy a multidimensional state space rather than fitting simple binary “resting vs activated” or M1/M2 frameworks, and it revisited concepts such as homeostatic and disease-associated signatures and the microglial sensome. Scientifically, this reframing improves interpretation of microglial heterogeneity in brain development, homeostasis, and disease.

Eggen BJL, Kooistra SM · Nature reviews. Neuroscience · (2026) · View on PubMed ↗

Complement dysregulation during the early phases of synucleinopathy.

This study investigated complement dysregulation during early synucleinopathy using a rat α-syn pre- (truncated in the abstract) model to determine whether complement activation is directly triggered by pathological α-syn versus occurring only after overt neurodegeneration. The key finding (as framed by the abstract) is that complement activation can be assessed in early phases to clarify whether α-syn pathology itself drives complement changes. This is significant for understanding immune mechanisms in Parkinson’s disease and for identifying potential early therapeutic targets in the complement pathway.

Khan H, Gifford M, Kordbacheh A et al. · Acta neuropathologica · (2026) · View on PubMed ↗ · Free PDF ↗

---

Infectious Disease: Viral Pathogenesis & Host-Directed Therapies

Viral syncytia evolve to resist interferon.

Researchers studied SARS-CoV-2 and Spike (S)-replacement vesicular stomatitis virus (VSV) to test whether viral syncytia formation drives evolution toward interferon resistance in cultured cells, human lung cell cultures, and hACE2 transgenic mice. They found that S-mediated syncytia impair interferon antiviral effects and that Spike substitutions modulating syncytia formation in Delta and Omicron similarly affect interferon resistance, also reducing antibody-mediated neutralization. This is significant because it links a viral cell-fusion phenotype to immune evasion and evolutionary fitness.

Li T, Kang I, Ye J et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Mapping in-cell protein contact sites reveals hijacking of paraspeckles during influenza A virus infection.

This research mapped influenza A virus (IAV)–host protein-protein contact sites in native cellular context using in-cell cross-linking mass spectrometry combined with structural modeling and functional assays in human cells infected with IAV. It revealed previously unrecognized virus-host interactions, including host factors linked to maturation of distinct haemagglutinin glycoforms via the membrane-bound endoplasmic reticulum–Golgi system and progressive disruption of nuclear processes. These mechanistic contact-site maps can identify actionable host pathways hijacked by IAV and improve understanding of viral replication and immune-relevant protein processing.

Kotova I, Mühlberg L, Gilep K et al. · Nature microbiology · (2026) · View on PubMed ↗ · Free PDF ↗

All-trans retinoic acid suppresses systemic inflammation induced by severe fever with thrombocytopenia syndrome virus in mice.

This study examined all-trans retinoic acid (ATRA) in severe fever with thrombocytopenia syndrome virus (SFTSV) infection, including observations in patients and mechanistic testing in an SFTSV mouse model. It found that patients had depleted serum vitamin A/ATRA levels associated with worse systemic inflammatory response syndrome severity and mortality, and that intraperitoneal ATRA suppressed virus-induced hyperinflammation via PPARγ-mediated downregulation of macrophage AP-1 transcriptional activity. The work suggests ATRA as a potential host-directed anti-inflammatory strategy to reduce lethal systemic inflammation during SFTSV infection.

Yu X, Wu J, Yin X et al. · Nature microbiology · (2026) · View on PubMed ↗

Viral protease-initiated lytic cell death as a universal antiviral mRNA therapy.

This preclinical study developed a universal antiviral mRNA platform called viral protease-initiated lytic cell death (VID), engineering gasdermin-D (GSDMD) with viral protease-specific cleavage motifs to trigger lytic cell death selectively in virus-infected cells. Using hepatitis A virus (HAV) as a model, lipid nanoparticle (LNP)-encapsulated VIDA mRNA abolished viral replication and shedding in vivo and reduced liver injury by coordinating a “kill-ahead” antiviral effect. The work suggests a broadly applicable mRNA strategy that leverages viral protease activity to induce targeted, immune-relevant cell death.

Li L, Yan XL, Wang HY et al. · Cell · (2026) · View on PubMed ↗

Divergent Autophagy Pathways in Plasmodium: Mechanisms, Functions, and Therapeutic Potential.

This review examined autophagy mechanisms in the malaria parasite Plasmodium, focusing on the reduced but functional autophagy-related (ATG) protein repertoire and the role of ATG8. It reports that Plasmodial ATG8 shows branched localization and associates with the apicoplast membrane, implying divergent autophagy pathways with functions beyond canonical bulk degradation. These parasite-specific insights suggest new therapeutic targets within Plasmodium autophagy machinery, particularly around ATG8/apicoplast-linked processes.

Rajput S, Mehra P, Nandi R et al. · Molecular microbiology · (2026) · View on PubMed ↗

---

Infectious Disease: Diagnostics & Vaccines

Circulating alpha-1 antitrypsin and its c-terminal peptides differentiate bacterial from viral community-acquired pneumonia.

Researchers studied whether circulating alpha-1 antitrypsin (AAT) and nine AAT-derived C-terminal peptides can distinguish bacterial from viral community-acquired pneumonia in 81 prospectively enrolled adults at hospital admission (day 0) and day 3. Using ELISA for AAT and LC-based quantification for the peptides, the study found that AAT/peptide profiles can differentiate bacterial versus viral CAP. This could reduce inappropriate antibiotic use by providing a more accurate, blood-based diagnostic approach early in illness.

Pashai Fakhri M, Börner FR, Held J et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial.

This randomized clinical trial evaluated clesrovimab, a long-acting monoclonal antibody, in infants at increased risk for severe respiratory syncytial virus (RSV) disease across two RSV seasons, comparing clesrovimab (105 mg) with palivizumab during season 1 and assessing safety/tolerability of 210 mg clesrovimab in season 2. The study focused on safety and tolerability outcomes for children who remained at increased risk for severe disease. The results inform dosing and risk management for extended RSV prophylaxis beyond a single season in high-risk infants.

Zar HJ, Bont LJ, Manzoni P et al. · JAMA pediatrics · (2026) · View on PubMed ↗

---

Cardiovascular Disease: Mechanisms & Therapeutic Targets

Does Characterization of Phenotypic Heterogeneity Provide Mechanistic Insights or Influence the Response to Treatment? Experience in Positive and Neutral Trials in Patients With Heart Failure and a Preserved Ejection Fraction.

This article reviewed and analyzed whether characterizing phenotypic heterogeneity in heart failure with preserved ejection fraction (HFpEF) can provide mechanistic insights or predict treatment response, drawing on experience from positive and neutral HFpEF trials. The authors concluded that despite extensive subgrouping efforts, phenotypic heterogeneity characterization has not reliably identified responders to therapy in neutral trials. Scientifically, the work argues for more rigorous causal frameworks and trial designs beyond descriptive heterogeneity to enable precision treatment in HFpEF.

Packer M, Schiattarella GG, Petrie MC et al. · Circulation · (2026) · View on PubMed ↗ · Free PDF ↗

Loss of ATP-Dependent Citrate Lyase Drives Left Ventricular Dysfunction by Metabolic Remodeling.

This study investigated the role of ATP-dependent citrate lyase (ACLY/Acly) in human heart tissue and models of nonischemic cardiomyopathy, using CRISPR-based approaches to test how loss of ACLY affects cardiac metabolism and function. Loss of ACLY drove left ventricular dysfunction through metabolic remodeling, consistent with impaired acetyl-CoA production and downstream lipid synthesis programs. These findings position ACLY as a metabolic regulator and potential therapeutic target in heart failure pathophysiology.

Liu S, Gammon ST, Tan L et al. · Circulation · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Small Extracellular Vesicles From Cardiomyocytes Activate Microglia Aggravating HFpEF.

This mouse study investigated whether small extracellular vesicles (sEVs) released from cardiomyocytes activate hypothalamic microglia and worsen heart failure with preserved ejection fraction (HFpEF). Using an HFpEF model combining long-term high-fat diet with the nitric oxide synthase inhibitor L-NAME, the authors found microglial activation and hypothalamic inflammation, and showed that microglial depletion with PLX3397 suppressed downstream sympathetic activation (with additional mechanistic effects reported in the full text). These findings support a heart-to-brain inflammatory mechanism in HFpEF mediated by cardiomyocyte sEVs and microglia, suggesting potential therapeutic targets in neuroinflammation/sympathetic pathways.

Men L, Wang Q, Ren B et al. · Circulation research · (2026) · View on PubMed ↗

Activity-based proteomics analysis revealed that DNJ directly targeted ATP5F1 to alleviate high glucose induced cardiomyocyte injury.

This study investigated the cardioprotective mechanism of the natural alkaloid 1-deoxynojirimycin (DNJ) in high-glucose–injured cardiomyocytes by using activity-based protein profiling (ABPP) to identify direct DNJ targets and then validating the mechanism around ATP5F1. The key finding was that DNJ directly targeted ATP5F1 and that this interaction alleviated mitochondrial injury and cardiomyocyte damage induced by high glucose. Scientifically, it defines a specific molecular target (ATP5F1) for DNJ, providing a mechanistic basis for developing targeted therapies for diabetic cardiomyopathy.

Li X, Chen Y, Yang H et al. · Cell communication and signaling : CCS · (2026) · View on PubMed ↗ · Free PDF ↗

---

Critical Care, Hemostasis & Perioperative Outcomes

Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial.

This multicenter, randomized, double-blind phase 3 clinical trial (SWOG S1600) studied whether perioperative specialized immunonutrition reduces 30-day complications versus standard oral nutrition support in adults undergoing radical cystectomy for bladder cancer. The trial tested an immune-enhancing nutritional intervention around surgery and evaluated postoperative complication outcomes as the primary endpoint. If effective, this strategy could improve perioperative care by reducing morbidity through modulation of immune function during major cancer surgery.

Hamilton-Reeves JM, Unger JM, Holzbeierlein JM et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

PROSPECT guideline for total hip arthroplasty: updated systematic review and procedure-specific postoperative pain management recommendations.

This PROSPECT collaboration updated systematic review evaluated evidence for procedure-specific postoperative pain management after elective primary total hip arthroplasty, focusing on analgesic and surgical interventions. It searched randomized controlled trials and systematic reviews from January 2020 to June 2024 to update the 2021 PROSPECT total hip arthroplasty recommendations, particularly incorporating newer evidence on motor-sparing regional techniques (abstract truncated). Clinically, the guideline aims to standardize effective, safe multimodal pain control strategies that improve functional recovery after total hip arthroplasty.

Carella M, Bugada D, Van de Velde M et al. · Anaesthesia · (2026) · View on PubMed ↗ · Free PDF ↗

Sustainable miniaturized smartphone-coupled TLC platform for innovative cleaning validation: application to tizanidine combinations under challenging concentration ratios.

This work developed a sustainable, miniaturized smartphone-coupled TLC platform for at-line pharmaceutical cleaning validation and applied it to quantify tizanidine (TZN) in combination with aceclofenac (ACF), ibuprofen (IBF), and paracetamol (PRC) under challenging concentration ratios. The key finding is that the platform enables rapid, portable determination of TZN carryover/contamination in multi-drug cleaning scenarios. This is clinically relevant for improving routine monitoring and reducing cross-contamination risk for a narrow therapeutic index, high-abuse-potential drug like tizanidine.

Abd El-Aziz MO, Nadim AH, Monir HH et al. · Scientific reports · (2026) · View on PubMed ↗ · Free PDF ↗

Hemoperfusion during extracorporeal membrane oxygenation: an updated systematic review and meta-analysis of 8,151 patients.

This systematic review and meta-analysis (8,151 adults) assessed whether adding hemoperfusion to extracorporeal membrane oxygenation (ECMO + HP vs ECMO alone) improves outcomes in adults. The key finding is the pooled estimate of hemoperfusion’s effect on all-cause mortality and safety, with subgroup analyses by study design (RCT vs non-RCT), ECMO type (VA vs VV), and etiology (cardiogenic shock vs cardiac arrest). Clinically, it aims to clarify whether hemoperfusion should be routinely considered during ECMO for specific patient subgroups.

Xie T, Yang C, Tao H et al. · Critical care (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Sodium bicarbonate therapy in severe metabolic acidemia: an individual patient data meta-analysis of the BICAR-ICU and BICAR-ICU2 trials.

This individual patient data meta-analysis combined the BICAR-ICU and BICAR-ICU2 randomized trials to evaluate intravenous sodium bicarbonate (titrated to pH ≥ 7.30) versus no bicarbonate in adults with severe metabolic acidemia (pH ≤ 7.20). The key finding is the pooled effect on 90-day mortality and renal replacement therapy (RRT) use, including assessment of heterogeneity across prespecified subgroups. This directly informs critical-care decision-making on bicarbonate use in severe acidemia and identifies which patient groups may benefit.

Fosset M, Pensier J, Jabaudon M et al. · Critical care (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Lyophilized platelet derived extracellular vesicles promote hemostasis and attenuate intracranial hemorrhage following traumatic brain injury.

This study evaluated whether lyophilized platelet-derived extracellular vesicles (LPEVs) reduce intracranial hemorrhage (ICH) and preserve blood–brain barrier (BBB) integrity after traumatic brain injury (TBI) using characterization (flow cytometry, scanning electron microscopy, Nanosight), in vitro human brain endothelial barrier assays, and a murine TBI model. The key finding was that LPEVs promoted hemostasis and attenuated ICH while maintaining BBB integrity following TBI. This supports LPEVs as a translational, cell-derived therapeutic strategy to improve acute outcomes after TBI-related hemorrhage.

Trivedi A, Miyazawa B, Fields AT et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

---

Respiratory Medicine: ARDS, Asthma, COPD & Upper Airway Disease

Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.

This article describes the phase III LUNA clinical programme design—four randomized, double-blind, placebo-controlled studies—evaluating tozorakimab (anti–IL-33 monoclonal antibody) in symptomatic COPD patients at high risk of exacerbations. It specifies that tozorakimab inhibits both IL-33 reduced (IL-33red) and oxidised (IL-33ox) activity and that participants receive optimized inhaled therapy with tozorakimab or placebo. The programme aims to determine whether IL-33 blockade improves efficacy and safety outcomes in a clinically relevant COPD population prone to frequent exacerbations.

Watz H, Sciurba FC, Bonini M et al. · BMJ open respiratory research · (2026) · View on PubMed ↗ · Free PDF ↗

COVID-19 and Global Perinatal Health: Lessons Learned on Maternal-Neonatal Outcomes, Infant Feeding Practices, and Healthcare Economics Across Income Settings.

This narrative review synthesized evidence on how the COVID-19 pandemic affected maternal-neonatal outcomes, infant feeding practices, and healthcare economics across high-income countries and low- and middle-income countries. It found that both direct SARS-CoV-2 infection and indirect healthcare-system disruption were associated with worse perinatal outcomes, altered breastfeeding practices, and substantial financial burden on healthcare institutions, with impacts differing by income setting. These cross-setting lessons highlight where maternal-newborn care and breastfeeding support should be prioritized during future respiratory pandemics and health-system shocks.

Gunasekaran V, Woo S, Shetty AK et al. · American journal of perinatology · (2026) · View on PubMed ↗

Use of tezepelumab for chronic rhinosinusitis with nasal polyps by eosinophilic endotype: WAYPOINT post-hoc analysis.

This post-hoc analysis of the phase 3 WAYPOINT randomized trial evaluated tezepelumab 210 mg versus placebo every 4 weeks in Japanese adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), stratified by eosinophilic chronic rhinosinusitis defined by the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (ECRS). Tezepelumab improved nasal polyp burden and sinonasal symptoms and reduced the need for surgery and systemic corticosteroids across eosinophilic subgroups, with an overall safety profile consistent with prior results. The findings support tezepelumab as an effective, endotype-informed biologic option for CRSwNP in Japanese patients with eosinophilic disease.

Fujieda S, Otori N, Han JK et al. · Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Prone positioning in ARDS.

This article reviewed the evidence and clinical role of prone positioning in acute respiratory distress syndrome (ARDS), including early use in intubated patients with PaO2/FiO2 <150 mmHg and the awake prone position (APP) approach used during and after the COVID-19 era. The key finding is that prone positioning consistently improves oxygenation in both intubated and non-intubated settings, with APP requiring further confirmation in non-COVID patients and routine ICU practice. The review is clinically significant because it supports prone positioning as a lung-protective mechanical ventilation strategy while highlighting where evidence gaps remain.

Ehrmann S, Li J, Liu L et al. · Intensive care medicine · (2026) · View on PubMed ↗ · Free PDF ↗

The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma.

This study compared airway transcriptomes in severe asthma patients with type 2 (T2) cytokine biomarker-high versus biomarker-low phenotypes using bronchial biopsies and brushes. In the UK Refractory Asthma Stratification Programme cohort (18 T2-high, 23 T2-intermediate, 11 T2-low) plus 20 healthy controls, and with sampling pre- and post-treatment with high-dose inhaled corticosteroids (ICS), the authors identified dysregulated genes and pathways associated with T2 suppression (full gene/pathway results truncated). The significance is that it helps define molecular drivers of T2-low severe asthma, potentially enabling biomarker-guided therapies beyond corticosteroid responsiveness.

Shen J, Chaudhuri R, Bicknell S et al. · Allergy · (2026) · View on PubMed ↗ · Free PDF ↗

---

Autoimmune & Inflammatory Disorders (Non-cancer)

Endothelial cell-intrinsic NOD2 signaling regulates the intestinal immune response through the generation of effector and memory T cells.

This study investigated how endothelial cell-intrinsic NOD2 signaling regulates intestinal immunity by using NOD2 engagement with muramyl dipeptide to drive T cell responses in the context of Crohn’s disease–relevant biology. It showed that NOD2 signaling promotes intestinal T cell homeostasis by generating effector and memory T cells, resolving a key innate-to-adaptive cross-talk mechanism underlying intestinal immune regulation. These findings clarify how NOD2 variants can contribute to Crohn’s disease despite NOD2 ligands being immunostimulatory, informing targeted therapeutic strategies that modulate NOD2-driven T cell programming.

Tsankov BK, Denney M, Ahn JSY et al. · Nature immunology · (2026) · View on PubMed ↗ · Free PDF ↗

The 2026 British Society for Rheumatology guideline for pain management in people with inflammatory arthritis.

This work presents the 2026 British Society for Rheumatology guideline for pain management in people with inflammatory arthritis (IA), synthesizing evidence from electronic health record analyses and patient survey data. It highlights that UK practice often relies on long-term opioids and gabapentinoids despite limited trial evidence, and that supportive non-pharmacological approaches with trial evidence are underused. The guideline provides an evidence-based, life-course framework to improve pain management strategies specifically for inflammatory arthritis.

Scott IC, Smith TM, Babatunde O et al. · Rheumatology (Oxford, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Unlocking Sulforaphane’s Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons.

This preclinical study compared sulforaphane (SF) with omaveloxolone (Omav) and dimethyl fumarate (DMF) in induced pluripotent stem cell (iPSC)-derived sensory neurons from Friedreich ataxia patients carrying expanded GAA repeats in FXN (including a line with 550 GAA1 repeats). The key finding was that SF further supported FXN expression and modulated epigenetic, inflammatory, and oxidative stress pathways in these patient-derived neurons, aligning with or extending prior observations. This is clinically significant because it strengthens the therapeutic rationale for SF as a potential adjunct or alternative strategy alongside the only approved FRDA therapy, omaveloxolone.

Yang W, Thompson B, Miellet S et al. · Antioxidants & redox signaling · (2026) · View on PubMed ↗

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

The POETYK PsA-2 phase 3 randomized, double-blind trial evaluated the efficacy and safety of deucravacitinib, an oral selective TYK2 inhibitor, in patients with active psoriatic arthritis (PsA) who were biologic-naïve or previously treated with tumor necrosis factor inhibitors. Over 52 weeks, patients were randomized to deucravacitinib 6 mg daily, placebo, or apremilast 30 mg twice daily (safety reference), with the primary endpoint based on ACR20 improvement (details truncated in the abstract). If the results confirm superiority and acceptable safety, deucravacitinib would provide an additional targeted oral option for PsA with potentially different efficacy/safety trade-offs than apremilast and placebo.

Mease PJ, Chandran V, Armstrong AW et al. · Arthritis & rheumatology (Hoboken, N.J.) · (2026) · View on PubMed ↗

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial.

This randomized trial studied ruxolitinib cream in adults (≥18 years) with moderate atopic dermatitis (IGA 3, EASI >7, itch NRS ≥4) who had inadequate response, intolerance, or contraindications to topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) within the prior 12 months in the TRuE-AD4 study (NCT06238817). After 8 weeks, ruxolitinib cream improved atopic dermatitis signs and symptoms compared with the control regimen (details truncated in the abstract). These findings support ruxolitinib cream as a potential next-line topical therapy for TCS/TCI-refractory moderate AD, potentially delaying or reducing the need for systemic escalation.

Carrascosa JM, Prajapati VH, Hong HC et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · (2026) · View on PubMed ↗ · Free PDF ↗

Associations of viral infections and antiviral vaccinations with anti-NMDAR and other forms of autoimmune encephalitis.

This systematic literature review examined reported associations between viral infections and antiviral vaccinations and the occurrence of autoimmune encephalitis (AIE), including anti-NMDAR and other AIE subtypes. The study synthesized published case evidence to characterize which viral triggers and vaccine exposures have been linked to specific AIE forms and how frequently these links are reported (full quantitative results are truncated). Clinically, mapping these immunological triggers can inform risk counseling and hypothesis generation for mechanisms driving autoantibody generation in AIE.

Bamberg S, Schulte-Frankenfeld PM, Kreye J · Brain, behavior, & immunity - health · (2026) · View on PubMed ↗ · Free PDF ↗

Mitochondria-targeted MXene-based nanozymes promote mitophagy and inhibit mtDNA-triggered cGAS/STING inflammation in osteoarthritis.

This preclinical study developed a mitochondria-targeted MXene-based nanozyme (MS@PMXene-TK) incorporating a mitochondria-targeting peptide (MTP-131) and a ROS-responsive thioketal-linked PEG-TK shell to treat osteoarthritis models. The nanozyme promoted mitophagy and inhibited mtDNA-triggered cGAS/STING inflammatory signaling, thereby reducing inflammation relevant to OA pathophysiology (full experimental outcomes truncated). These findings suggest a subcellularly targeted therapeutic strategy that couples mitochondrial quality control with suppression of cGAS/STING-driven innate immune activation in osteoarthritis.

Li T, Zheng A, Zhu C et al. · Bioactive materials · (2026) · View on PubMed ↗ · Free PDF ↗

Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study.

This retrospective real-world comparative study evaluated telitacicept versus conventional immunotherapy in patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR-Ab+ gMG), including broader eligibility than prior randomized trials. After propensity score matching (1:1; 35 patients per group), telitacicept was compared with conventional therapy for treatment response and safety outcomes (primary results truncated in the abstract). The study supports evidence generation for telitacicept’s effectiveness and tolerability in routine practice, informing treatment selection for AChR-Ab+ gMG.

Yang Y, Kang N, Zhu Y et al. · ImmunoTargets and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Efficacy of magnesium-calcium ionic oral rinse for primary burning mouth syndrome: a randomized, double-blind, placebo-controlled trial.

This randomized, double-blind, placebo-controlled trial tested whether a magnesium–calcium ionic oral rinse improves symptoms and safety in patients with primary burning mouth syndrome (BMS). The key finding was that the magnesium–calcium oral rinse was effective compared with placebo in managing primary BMS (with outcomes reported as part of the trial’s efficacy endpoints). Clinically, it suggests a local, low-systemic-adverse-effect approach by modulating the oral ionic microenvironment for a chronic orofacial pain condition.

Carrió N, Garawani BE, Alahmad A et al. · BMC oral health · (2026) · View on PubMed ↗ · Free PDF ↗

---

Lifestyle, Aging, and Preventive Health

EndoBridge 2025: pearls and highlights.

EndoBridge 2025 was studied as a scientific meeting (not a biomedical experiment) covering major topics in endocrinology and metabolism, including pituitary, thyroid, adrenal, bone metabolism, neuroendocrine tumors, diabetes, obesity, clinical nutrition, and lipid abnormalities. The key finding is that the congress delivered state-of-the-art lectures and interactive case discussions with broad expert participation and a wide thematic program. Scientifically and clinically, it serves as a platform for disseminating current advances that can inform future research directions and clinical practice.

Yildiz BO, Armenti M, Brandi ML et al. · Hormones (Athens, Greece) · (2026) · View on PubMed ↗

Genome-wide association analyses of borderline personality disorder identify 11 loci and highlight shared risk with mental and somatic disorders.

This study performed the largest genome-wide association study meta-analysis of borderline personality disorder (BPD) in European-ancestry participants (12,339 BPD cases and 1,041,717 controls in discovery; 685 cases and 107,750 controls in replication). It identified 11 independent associated genomic loci and 9 risk genes, with SNP-heritability of 17.3% and polygenic scores explaining 4.6% of BPD liability-scale variance. These findings refine the genetic architecture of BPD and highlight shared genetic risk with both mental and somatic disorders, supporting cross-disorder biology for future risk prediction and mechanism studies.

Streit F, Awasthi S, Hall ASM et al. · Nature genetics · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Effect of high-dose versus standard-dose influenza vaccines on hospitalisation outcomes and mortality in older adults: a systematic review and meta-analysis.

This systematic review and meta-analysis compared high-dose versus standard-dose inactivated influenza vaccines (HD-IIV 60 μg haemagglutinin per strain vs SD-IIV) using randomized controlled trials in adults aged 65 years or older. It assessed effects on hospitalization outcomes and mortality to determine whether higher antigen dosing improves clinical outcomes in this population. The results are intended to inform vaccine policy and dosing recommendations for older adults at highest risk of severe influenza.

Zhao W, Lian R, Zhao Y et al. · The lancet. Healthy longevity · (2027) · 1 citations · View on PubMed ↗ · Free PDF ↗

Multidomain Lifestyle Intervention in Mild Cognitive Impairment: Subgroup Analysis of the SUPERBRAIN-MEET Randomized Trial.

This prespecified subgroup analysis of the 24-week, multicenter, outcome-assessor-blinded SUPERBRAIN-MEET randomized trial studied whether the cognitive effects of a multidomain lifestyle intervention (MLI) delivered via face-to-face sessions plus digital platforms differed by sociodemographic characteristics, digital readiness, baseline cognitive status, and vascular risk in adults with mild cognitive impairment (MCI). The MLI’s cognitive benefits varied across subgroups defined by these baseline factors, indicating that responsiveness is not uniform across patient profiles. These findings support tailoring multidomain lifestyle programs for MCI by identifying which patient characteristics predict greater cognitive benefit.

Kim DA, Lee SM, Sun K et al. · Neurology · (2026) · View on PubMed ↗

Accelerated Epigenetic and Inflammatory Aging and Intrinsic Capacity.

This population-based cohort study examined cross-sectional and longitudinal associations between accelerated epigenetic aging and accelerated inflammatory aging with intrinsic capacity (IC), a WHO-defined composite of physical and mental capacities, in older adults. Accelerated epigenetic and inflammatory aging were associated with lower IC and with domain-specific declines, supporting molecular links to functional aging trajectories. These findings support using epigenetic and inflammatory biomarkers to identify individuals at risk for reduced intrinsic capacity and to guide preventive interventions.

Rouch L, De Souto Barreto P, Rolland Y et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy.

This study assessed the population health impact of the 2026 American Heart Association/American College of Cardiology/multisociety dyslipidemia guideline on primary prevention statin eligibility among nonpregnant adults aged 30–79 years without known ASCVD using NHANES 2017–2023 data. The guideline’s updated ASCVD risk estimation and expanded statin-eligible populations were projected to change the proportion of adults recommended for primary prevention statin therapy. These findings are clinically significant for anticipating how guideline revisions may affect preventive cardiovascular outcomes at the population level.

Anderson TS, Wilson LM, Sussman JB · JAMA · (2026) · View on PubMed ↗

Effects of Lifestyle Modification on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis evaluated whether lifestyle modification reduces intrapancreatic fat deposition (IPFD) in humans by synthesizing PubMed/Embase studies. Across included evidence, lifestyle interventions showed beneficial effects on IPFD, supporting IPFD as a modifiable ectopic fat depot linked to pancreatic disease risk. The results are scientifically significant because they strengthen the rationale for lifestyle-based strategies to target pancreatic metabolic risk beyond liver fat.

Ahmad S, Sul HH, Danpanichkul P et al. · Current obesity reports · (2026) · View on PubMed ↗ · Free PDF ↗

GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.

This target trial emulation study used Veterans Health Administration data to compare overdose risk among Veterans with type 2 diabetes and opioid use disorder who initiated semaglutide or tirzepatide versus other diabetes medications (e.g., insulin, metformin, sulfonylurea, SGLT2 inhibitors). The key finding was that GLP-1 receptor agonist initiation was associated with a change in all-cause overdose risk relative to comparator diabetes therapies. The results are clinically significant because they help clarify whether GLP-1RAs can reduce overdose risk in a high-risk real-world population with OUD.

Kennedy KP, Bremseth-Vining R, Lynch KG et al. · The Journal of clinical psychiatry · (2026) · View on PubMed ↗

Gut Metabolism Links Precision Nutrition, Exercise, and Healthspan in Drosophila melanogaster.

This Drosophila melanogaster study tested whether a precision-nutrition and exercise multimodal intervention affects healthspan and lifespan, using a chemically defined diet (CDD) and combining methionine restriction (MR), taurine supplementation (Tau), and moderate exercise. The combination additively extended lifespan while preserving reproductive capacity and improving locomotor function, and targeted metabolomics with stable isotope tracing indicated increased mitochondrial TCA cycle flux and improved gut redox homeostasis. Scientifically, it links gut metabolism and mitochondrial energy flux to the trade-off between longevity and physiological performance, informing how dietary components and exercise may jointly promote healthspan.

Wei F, Liu S, Sun Y et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

Multiomics integrative bioinformatics analysis of gene expression characteristics and molecular mechanisms in preeclampsia placental tissue.

This integrative multiomics bioinformatics study analyzed preeclampsia placental tissue by combining multiple placental transcriptome datasets and single-cell sequencing datasets from the Gene Expression Omnibus (GEO). Using differential expression analysis, Weighted Gene Co-expression Network Analysis (WGCNA), and machine learning to define molecular subtypes and mechanisms (with additional methods truncated), it aimed to identify gene expression characteristics and pathways driving placental dysfunction in preeclampsia. The scientific significance is that it may yield candidate biomarkers and mechanistic targets for stratifying preeclampsia and improving understanding of its placental pathogenesis.

Li N, Tian L, Wei H · Artificial cells, nanomedicine, and biotechnology · (2026) · View on PubMed ↗ · Free PDF ↗

Medical Students’ Attitudes, Perceptions, and Self-Reported Familiarity With Artificial Intelligence in Healthcare: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis synthesized studies reporting medical students’ attitudes, perceptions, and self-reported familiarity with artificial intelligence (AI) in healthcare. It focused on harmonizing constructs across heterogeneous survey instruments and examined variation across settings, including heterogeneity, prediction intervals, risk of bias, and certainty of evidence (details truncated). The clinical/educational significance is that it clarifies how future clinicians currently understand AI, informing curriculum design and targeted training to address gaps and misconceptions.

Zhang W, Han J, Han X et al. · JMIR medical education · (2026) · View on PubMed ↗ · Free PDF ↗

Durability and Safety of Imeglimin as an Add-On to DPP-4 Inhibitors in Japanese Type 2 Diabetes: The 104-Week FAMILIAR Trial.

This multicenter randomized placebo-controlled trial (FAMILIAR) evaluated imeglimin as an add-on to DPP-4 inhibitors in Japanese adults with type 2 diabetes inadequately controlled on DPP-4 monotherapy, with emphasis on 104-week glycemic durability and safety in elderly patients. The primary endpoint was change in HbA1c from baseline to week 104, with all participants receiving imeglimin after a 24-week double-blind phase (details of effect sizes truncated). The long-term results support the durability and tolerability of imeglimin combination therapy in Japanese clinical practice, particularly for older patients.

Shimoda M, Osonoi T, Iwamoto M et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗

Peptide LKLKLL is a more effective component of Akkermansia muciniphila which regulate glucolipid metabolism through GLP-1/GIP dual modulation.

This study tested whether the Akkermansia muciniphila–derived hexapeptide LKLKLL can modulate incretin signaling and improve metabolic outcomes in cellular and animal models. It found that LKLKLL promotes GLP-1 and GIP secretion (including in STC-1 cells) and reduces body weight and improves glucose tolerance in high-fat diet–induced obese and diabetic mouse models. These findings position LKLKLL as a defined microbial component that could be developed to treat obesity and diabetes via GLP-1/GIP dual modulation.

Li Y, Ye D, Fu C et al. · Gut microbes · (2026) · View on PubMed ↗ · Free PDF ↗

Electroacupuncture Treatment on Sarcopenia in Patients Undergoing Maintenance Haemodialysis: An Effective Therapy.

This randomized controlled clinical study evaluated electroacupuncture (EA) as a treatment for sarcopenia in patients undergoing maintenance haemodialysis (MHD). In 36 participants randomized to EA versus control, EA delivered 24 sessions over 8 weeks (30 minutes, three times weekly) was tested for efficacy on sarcopenia outcomes. The clinical significance is that EA may offer a nonpharmacologic adjunct to improve sarcopenia in MHD patients, pending confirmation of the reported outcome differences.

Chen R, Qian Q, Wang B et al. · Journal of cachexia, sarcopenia and muscle · (2026) · View on PubMed ↗ · Free PDF ↗

Evaluating the pharmacokinetics, efficacy and safety of low-dose cannabidiol.

This article reviewed pharmacokinetics (PK), pharmacodynamics (PD), and safety evidence for low-dose cannabidiol (CBD) at doses ≤2.5 mg/kg or ≤175 mg/day. It reports that low-dose oral CBD produces substantially lower systemic exposure (Cmax and AUC) than typical Epidiolex dosing and shows very limited evidence of physical or neurological PD effects in healthy volunteers. The significance is that current data suggest low-dose CBD may have minimal measurable effects, informing dosing and safety expectations for non-prescription CBD use.

Warren WG, Osborn M, Yates A et al. · British journal of clinical pharmacology · (2026) · View on PubMed ↗

Frailty mediates the association between sleep duration and physical, psychological, and cognitive multimorbidity in Chinese middle-aged and older adults.

This study used data from the China Health and Retirement Longitudinal Study (CHARLS) to test whether frailty mediates the association between sleep duration and physical, psychological, and cognitive multimorbidity (PPC-MM) in Chinese middle-aged and older adults. Using multivariate logistic regression, Cox proportional hazards models, and restricted cubic spline analyses, it found that frailty accounts for part of the relationship between sleep duration and PPC-MM risk. These findings highlight frailty as a potential intervention target to reduce multimorbidity risk linked to abnormal sleep patterns.

Ding H, Li L, Luo G et al. · Scientific reports · (2026) · View on PubMed ↗ · Free PDF ↗

Gut microbiota-driven metabolites modulate the development of stress-related mental disorders.

This review synthesized evidence on how gut microbiota-driven metabolites influence the development of stress-related mental disorders (e.g., depression, anxiety, PTSD). The key finding is that microbiome alterations can change metabolite production and systemic exposure, thereby modulating host stress physiology through multiple biological pathways. Scientifically, it frames gut-derived metabolites as actionable mechanistic links that could guide future biomarker and therapeutic strategies for stress-related psychiatric disease.

Yuan M, Qin F, Wu L et al. · Translational psychiatry · (2026) · View on PubMed ↗ · Free PDF ↗

Work-to-sleep ratio as a novel marker of NAFLD risk: evidence from U.S. and Korean national cohorts.

This cohort study analyzed the Work-to-Sleep Ratio (WSR) as a behavioral marker of NAFLD risk using U.S. and Korean national cohorts. The key finding is that WSR is associated with NAFLD (MASLD) risk beyond what work hours or sleep duration alone capture, reflecting the balance between occupational demand and sleep recovery. Clinically, it suggests a practical, modifiable risk metric that could improve screening and prevention strategies for metabolic liver disease.

Zhong Y, Kou Y, Lu Z et al. · Nutrition & metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on July 24, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.